Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine, Vorinostat, and NK Cells for High Risk MDS
NCT01593670Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2013
- Primary completion
- Oct 2018
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Natural Killer Cells in myelodysplastic syndrome (MDS), sponsored by Masonic Cancer Center. Started Mar 2013; status: completed.
02
Drugs
Natural Killer Cells
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01593670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593670.